Valneva’s strategy stems from its vision to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. We aim to become the leading vaccine biotech by combining the growth of our commercial business with the development of prophylactic vaccine candidates.

Products

Growing product sales revenues to €200 million and beyond.

  • Valneva’s commercial business continues to grow and the Company aims to add products to its commercial portfolio, leveraging its commercial and industrial infrastructure.

R&D

Investing our profitable business revenues to fund key R&D programs.

  • Valneva’s profitable business funds key R&D programs.
  • Valneva is focused on generating long-term shareholder value and will continue to invest in advancing its key R&D programs including the two leading programs, Lyme disease (VLA15) and chikungunya (VLA1553).

Partnering

Collaboration is key to success in research and biotechnology.

  • Valneva collaborates with the world’s leading pharmaceutical and biotech companies, as well as research institutes.
  • We are continuously seeking new partners to develop innovative, life-changing vaccines.